Cellular labeling with 99mTc chelates: Relevance of in vitro and in vivo viability testing

Technetium-99m Pharmaceuticals: Preparation and Quality Control in Nuclear Medicine

Volumn , Issue , 2007, Pages 103-122

  Sinzinger, H ^a   Rodrigues, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889954379     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-33990-8_8     Document Type: Chapter

References (81)

1. 99mTc-oxine. Comparison of in vitro and clinical use for monitoring of kidney transplants. Progr Radiopharmacol 2:211-220
2. Arndt JW, van der Sluys Veer A, Blok K et al (1993) Prospective comparative study of technetium-99m-WBCs and indium-111-granulocytes for the examination of patients with inflammatory bowel disease. J Nucl Med 34:1052-1057
3. Badenhorst PN, Lotter MG, Heyns A et al (1982) The influence of the "collection injury" on the survival and distribution of indium-Ill-labelled canine platelets. Br J Haematol 52:233-240
4. Baldini MG, Myers TJ (1980) Utilité e limitazioni degli studi di soprawivenza delle piastrine. Una valutazione critica [in Italian]. Haematologica 65:689-716
5. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J (2003) Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108:863-868
6. 99™Tc- hexamethylpropyleneamine-oxime (HMPAO) as a platelet label: evaluation of labelling parameters and first in vivo results. Nucl Med Commun 9:831-842
7. mIn-oxine labelled granulocytes in man: first clinical results. Nucl Med Commun 9:435-437
8. Bengel FM, Schachinger V, Dimmeier S (2005) Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging 32:404-416
9. Berger CL, Ederson RL (1979) Comparison of lymphocyte function after isolation by Ficoll-Hypa-que flotation or elutriation. J Invest Dermatol 73:231-235
10. Berger HJ, Zaret BL (1984) Radionuclide assessment of cardiovascular performance: radiopharmaceuticals. In: Freeman LM (ed) Freeman and Johnson's clinical radionuclide imaging. Grune & Stratton, Orlando, Fla., pp 366-367
11. u'in-labelled white blood cells in the diagnosis of Felly's syndrome. J Clin Pathol 35:74-76
12. Bowring CS (1986) Imaging and quantitative scanning. In: Radionuclides in hematology. Lewis SM, Baily RJ (eds) Churchill Livingstone, Edinburgh, pp 151-172
13. Brenner W, Aicher A, Eckey T, Massoudi S, Zuhayra M, Koehl U, Heeschen C, Kampen WU, Zeiher AM, Dimmeler S, Henze E (2004) In-Ill-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 45:512-518
14. Bunting RW, Callahan RJ, Finkelstein S, Lees RS, William MS (1982) A modified method for labelling human platelets with indium-Ill oxine using albumin density-gradient separation. Radiology 145:219-221
15. Chervu LR, Huq SS, Joseph JA et al (1981) Medication-induced changes in biodistribution of radiopharmaceuticals. J Nucl Med 22:72
16. Chin BB, Nakamoto Y, Bulte JW, Pittenger MF, Wahl R, Kraitchman DL (2003) In-111-oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun 24:1149-1154
17. u'in-labelled neutrophils, platelets and lymphocytes. Trivirum, New York, pp 205-211
18. Chisholm PM, Danpure HJ, Healey G, Osman S (1979) Cell damage resulting from the labelling of rat lymphocytes and HeLa S3 cells with In-111-oxine. J Nucl Med 20:1308-1311
19. 99mTc- hexamethylpropyleneamine oxime. Nucl Med Commun 9:465-475
20. De Vries RA, De Bruin M, Marx JJM, Van De Wiel A (1993) Radioisotopic labels for blood cell survival studies: a review. Nucl Med Biol 20:809-817
21. Eckleman W, Richards P, Hauser W, Atkins H (1979) Technetium-labelled red blood cells. J Nucl Med 20:22-24
22. 99mTc from red cells and its effect on red cell volume measurement. J Clin Pathol 27:983-985
23. Fisher DG, Koren HS (1981) Isolation of human monocytes. Adams DO, Edelson PJ, Koren HS (eds) In: Methods for studying mononuclear phagocytes. Academic, New York, 43-47
24. Gorman, RR, Bunting S, Miller OV (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13:377-388.
25. Granegger S, Flores J, Widhalm K, Sinzinger H (1988) Increased low-density lipoproteins (LDL) negatively affect human labelling. Folia Haematol 115:451-453
26. Harker LA, Slichter SJ, Sauvage LR (1977) Platelet consumption by arterial prostheses: the effects of endothelialization and pharmacologic inhibition of platelet function. Ann Surg 186:594-601
27. Hawker RJ, Hawker LM, Wilkinson AR (1987) Indium-labelled human platelets. Optimal method. Clin Sei 58:243-248
28. Hegge FN, Hamilton GW, Larson SM et al (1978) Cardiac chamber imaging: a comparison of red blood cells labelled with Tc-99m in vitro and in vivo. J Nucl Med 19:129
29. Hladik WB, Nigg KK, Rhodes BA (1982) Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 12:184
30. International Committee For Standardization In Hematology (1988) Panel on diagnostic applications of radionuclides. Recommended method for indium-Ill platelet survival studies. J Nucl Med 29:564-566
31. 99mTc-ECD as a leukocyte labelling agent. Nucl Med Comm 15:294-297
32. Lantto EH, Lantto TJ, Vorne M (1991) Fast diagnosis of abdominal infections and inflammations with technetium-99m-HM-PAO labeled leukocytes. J. Nucl Med 32:2029-2034
33. Lee HB, Wexler JP, Scharf SC et al (1983) Pharmacologie alterations in Tc-99m binding by red blood cells: concise communication. J Nucl Med 24:397-401
34. 99m-labelling of red blood cells (RBCs) by RBC antibodies. J Nucl Med 21:44
35. Lötter MG, Heyns AD, Badenhorst PN et al (1987) Evaluation of mathematic models to assess platelet kinetics. J Nucl Med 27:1192-1201
36. Mathias CJ, Welch MJ (1979) Labelling mechanism and localization of indium-Ill in human platelets. J Nucl Med 20:659
37. Mathias CJ, Welch MJ (1984) Radiolabelling of platelets. Semin Nucl Med 14:118-127
38. McAfee JG, Subramanian G, Gagne G (1984) Technique of leukocyte harvesting and labeling: problems and perspectives. Semin Nucl Med 14:83-106
39. Molhson PL, Engelfriet CP, Contreras M (1987) The transfusion of platelets, leukocytes, haemo-poietic cells and plasma components. In: Blood transfusions in clinical medicine. Blackwell, Oxford, pp 7-27
40. Mortelmans L, Verbruggen A, De Roo M, Vermylen J (1986) Evaluation of three methods of platelet labeling. Nucl Med Comm 7: 519-529
41. 99mTc)D, L-HM-PAO J Nucl Med 30:2022-2028
42. Mountford PJ, Kettle AG, O'Doherty MH, Coakley AJ (1990) Comparison of technetium-99m-HM-PAO leukocytes with indium-lll-oxine leukocytes for localizing intraabdominal sepsis. J Nucl Med 31:311-315
43. Najean Y (1986) The choice of tracer for platelet kinetics and scintigraphic studies. Nucl Med Biol 13:159-164
44. Neirinckx R, Canning L, Piper I et al (1987) Technetium-99m-D, L-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 28:191-202
45. Peters AM (1988) Review of platelet labelling and kinetics. Nucl Med Commun 9:803-808
46. Peters AM, Saverymuttu SH, Danpure HJ, Osman S (1986) Cell labeling. In: Bailey RJ, Lewis SM (eds) Radionuclides in haematology. Churchill Livingstone, Edinburgh, pp 79-109
47. Porter WC, Dees SM, Freitas JE, Dworkin HJ (1983) Acid-citrate-dextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells. J Nucl Med 24:383-387
48. Rao SA, Knobel J, Collier D et al (1986) Effect of Sn (II) ion concentration and heparin on techne-tium-99m red blood cell labelling. J Nucl Med 27:1202-1206.
49. Raptopoulos V, Doherty PW, Goss TP et al (1982) Acute osteomyelitis: advantage of white cell scans in early detection. Am J Roentgenol 139:1077-1082
50. 11 Wium-Oxinf "'indium-Oxin-Sulfat und "™Tc-0xin zur Erythrozytenmarkierung [in German]. Wien Klin Wschr 3:120-123
51. Riordon F, Nelp WB (1982) Binding capacity of normal and sickle cell hemoglobin for technetium atoms. J Nucl Med 23:91
52. Roddie ME, Peters AM, Danpure HJ et al (1988) Inflammation: imaging with Tc-99m HM-PAO-la-belled leukocytes. Radiology 166:767-772
53. Rodrigues M, Sinzinger H (1994) Platelet labeling-methodology and clinical applications. Thromb Res 76:399-432
54. Sampson CB (1993) Adverse reactions and drug interactions with radiopharmaceuticals. Drug Saf 8:280-294
55. Sampson CB (1995) Influence of drugs on cell labelling. 6th European Symposium on Radiophar-macy and Radiopharmaceuticals. Graz, March 1995
56. Saverymuttu SH, Peters AM, Lavender JP et al (1983) Quantitative fecal indium-Ill labelled leukocyte excretion in the assessment of activity in Crohn's disease. Gastroenterology 85:1333.
57. mIn)8-hydroxyquino-line. J Nucl Med 20:524-531
58. Schneider W, Gear ARL (1994) Significance of glucose and glycogen metabolism for platelet function. Am J Physiol 3:225-232
59. 99mTc radiopharmaceuticals. Nucl Med Commun 15:845-849
60. Sfakianakis GN, Al-Sheikh W, Heal A et al (1982) Comparison of scintigraphy with In-Ill leukocytes and Ga-67 in the diagnosis of occult sepsis. J Nucl Med 23:618
61. Sfakianakis GN, Mnaymneh W, Ghandus-Mnaymneh L et al (1982) Positive In-Ill leukocyte scintigraphy in a skeletal metastasis. Am J Roentgenol 139: 601-603
62. mIn-oxine. Nucl Med Comm 9:597-601
63. 2)-addition for preparation and injection. J Nucl Med 22:292
64. Sinzinger H, Flores J, Widhalm K, Granegger S (1987a) Platelet viability (aggregation, migration, recovery) after radiolabelling of platelets from hypercholesterolemics using various tracers (oxine, oxine-sulphate, tropolone, MPO). Eur J Nucl Med 14:358-361
65. 2 improves recovery, but does not change platelet half-life and platelet uptake over active human lesion sites. Prostaglandins 33:787-790
66. Sinzinger H, Granegger S (2006) Radionuclide vascular imaging and characterization of human metabolic endothelial surface lining. Q J Nucl Med Mol Imaging 50:226-235
67. Sinzinger H, Kolbe H, Strobl-Jäger E, Höfer R (1984) A simple and safe technique for sterile autologous platelet labelling using "Monovette" vials. Eur J Nucl Med 9:320-322
68. 99mTc labelled autologous human granulocytes and radiation dose to cells and organs. Eur J Nucl Med 14:1-7
69. Srivastava S, Rao Chervu L (1984) Radionuclide-labelled red blood cells: current status and future prospects. Semin Nucl Med 14:68-82
70. 99mTc: progress and perspectives. Semin Nucl Med 20:41-51
71. Sweeney JD, Holme S, Heaton WAL, Nelson E (1995) White cell-reduced platelet concentrates prepared by in-line filtration of platelet-rich plasma. Transfusion 35:131-136
72. Tatum JL, Burke TS, Hirsh JI et al (1983) Pitfall to modified in vivo method of technetium-99m red blood cell labelling. Iodinated contrast media. Clin Nucl Med 8:585-587
73. Thakur ML, Welch MJ, Malech HL (1981) Indium-Ill labelled human platelets: improved method, efficacy and evaluation. J Nucl Med 22:381-385
74. Thierens HM, Vrai AM, Van-Haelst JP et al (1982) Lymphocyte labelling with technetium-99m-HM-PAO: a radiotoxicity study using the micronucleus assay. J Nucl Med 33:1167-1174
75. mIn-oxinate and tropolonate labelling on human platelet aggregation and/(-thromboglobulin release. In: Thakur ML, Ezekowitz MD, Hardeman MR (eds) Radiolabeled blood cellular elements. Plenum, New York
76. Uchida T, Nemoto T, Yui T et al (1979) Use of technetium-99m as a radioactive label to study migratory patterns of leukocytes. J Nucl Med 20:1197-2000
77. u 'indium platelet kinetics in normal human subjects: tropolone versus oxine methods. J Nucl Med 27:1669-1674
78. Wagner X, Granegger S, Dembinska-Kiec A, Sinzinger H (1998) Nitric oxide (NO) for radiolabel-ling of human platelets. In: Sinzinger H, Thakur ML (eds) Nuclear medicine research. Facultas, Vienna, p 58
79. Webber D, Nunan TO, Doherty JO (1994) The effect of varying type and volume of sedimenting agents on leukocyte harvesting and labelling in sickle cell patients. Nucl Med Comm 15:735-741
80. Wilson ME, Hung JC (1992) Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with Ultra Tag® RBC kit. J Nucl Med 33:306-307
81. 99mTc-labelled red blood cells. Semin Nucl Med 12:139-146